Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive Cerca de metade dos pacientes brasileiros recebendo natalizumabe para tratamento de esclerose múltipla tem DNA-JC vírus positivo

Objective: Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV) infection. The objective of the present study was to assess the prevalence of JCV-DNA in Brazilian patients using natalizumab. Method: Qualitative detection of the JCV in the serum was performed with real-time polymerase chain reaction (PCR). Results: In a group of 168 patients with MS who were undergoing treatment with natalizumab, JCV-DNA was detectable in 86 (51.2%) patients. Discussion: Data on JCV-DNA in Brazil add to the worldwide assessment of the prevalence of the JCV in MS patients requiring treatment with natalizumab.